Sponsor or institution

Clinical trials and research at IDEAYA Biosciences

• 7Clinical trials
• 22Countries

Newest trials

All recruiting trials (7)

• Adjuvant darovasertib and crizotinib in high-risk non-metastatic uveal melanoma

  Researchers are testing whether adding darovasertib and crizotinib after local eye tumor treatment can help prevent recurrence in people with high-risk, non-metastatic uveal melanoma.

  Recruiting at 4 sites Phase 3 IDEAYA Biosciences · Scottsdale, Arizona and 12 other locations · NCT07804186

• IDE574 for adults with advanced solid tumors: safety and early activity

  We will try IDE574 alone or with fulvestrant to see if it is safe and shows early benefit for adults with advanced ER+, HER2- breast cancer and several other solid tumors.

  Recruiting at 18 sites Phase 1 IDEAYA Biosciences · Santa Monica, California and 22 other locations · NCT07540572

• IDE034 for adults with advanced solid tumors that express B7-H3 and PTK7

  This trial will test IDE034 to see if it is safe and works in adults with advanced or metastatic solid tumors that express B7-H3 and PTK7.

  Recruiting at 26 sites Phase 1 IDEAYA Biosciences · Duarte, California and 25 other locations · NCT07503808

• IDE892 alone and with IDE397 for MTAP-deleted advanced solid tumors

  This trial tests IDE892 by itself and combined with IDE397 in adults whose advanced solid tumors have MTAP deletion and have progressed after standard treatments.

  Recruiting at 23 sites Phase 1 IDEAYA Biosciences · Goodyear, Arizona and 22 other locations · NCT07277413

• IDE849 for DLL3-expressing tumors including small-cell lung cancer

  This trial tests IDE849, alone and with durvalumab or IDE161, to see if it is safe and can shrink DLL3-positive tumors in people with small-cell lung cancer or other DLL3-expressing cancers.

  Recruiting at 13 sites Phase 1/2 IDEAYA Biosciences · Denver, Colorado and 12 other locations · NCT07174583

• Darovasertib before local treatment for primary uveal melanoma

  This trial tests whether giving darovasertib before surgery or radiation helps people with primary non-metastatic uveal melanoma.

  Recruiting at 25 sites Phase 3 IDEAYA Biosciences · Scottsdale, Arizona and 93 other locations · NCT07015190

• Evaluating IDE196 for patients with specific solid tumors

  This study is testing a new treatment called IDE196 for people with specific solid tumors that have certain genetic changes to see if it can help shrink their tumors and how safe it is.

  Recruiting at 7 sites Phase 1/2 IDEAYA Biosciences · Los Angeles, California and 14 other locations · NCT03947385

Quick answers

How many clinical trials run by IDEAYA Biosciences are recruiting right now?

7, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 22 countries. The most sites are in United States (7 trials), Canada (3 trials), Georgia (2 trials), Australia (2 trials), Spain (2 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 1: 3, Phase 1/2: 2, Phase 3: 2. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →